Novavax Completes Enrollment Of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season.

More: continued here

Filed under: Clinical Trials on May 18th, 2009